Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis

Neoplasma

Volumn 59, Issue 4, 2012, Pages 469-474

  Orendas, P ^a   Kubatka, P ^b,e   Kajo, K ^c,d   Stollarova, N ^e   Kassayova, M ^a   Bojkova, B ^a   Pec, M ^b,e   Nosal, V ^f   Kiskova, T ^a   Zihlavnikova, K ^b   Karsnakova, R ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d BB Biocyt   (Slovakia)

^e CATHOLIC UNIVERSITY IN RU OMBEROK   (Slovakia)

^f Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Bexarotene; Female rats; Mammary carcinogenesis; Melatonin; Prevention

Indexed keywords

BEXAROTENE; CHOLESTEROL; CORTICOSTERONE; GLUCOSE; GLYCOGEN; MALONALDEHYDE; MELATONIN; METHYLNITROSOUREA; PHOSPHOLIPID; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CARCINOGEN; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INCIDENCE; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; NONHUMAN; RAT; TUMOR VOLUME; ANIMAL; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL NEOPLASM; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; CARCINOGENS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 84864553994     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_060     Document Type: Article

References (28)

1. MOON RC, Grubbs CJ, Sporn MB. Inhibition of 7,12-dimetylbenz(a)anthracene-induced mammary carcinogenesis by retinyl acetate. Cancer Res 1976; 36: 2626-2630.
2. AHLERSOVA E, AHLERS I, KUBATKA P, BOJKOVA B, MOCIKOVA K et al. Melatonin and retinyl acetate as chemopreventives in DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats. Folia Biol (Prague) 2000; 46: 69-72.
3. BOJKOVA B, KUBATKA P, MOCIKOVA K, MNICHOVA M, AHLERSOVA E et al. Effects of retinyl acetate and melatonin on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. A preliminary report. Folia Biol (Prague) 2000; 46: 73-76.
4. MOON RC, MEHTA RG, DETRISAC CJ. Retinoids as chemopreventive agents for breast cancer. Cancer Detect Prevent 1992; 16: 73-80.
5. DRAGNEV HD, RIGAS JR, DMITROVSKY E. The retinoids and cancer prevention mechanisms. Oncologist 2000; 5: 361-368. http://dx.doi.org/10.1634/theoncologist.5-5-361
6. WONG SF. Oral bexarotene in the treatment of cutaneous T-cell lymphoma. Ann Pharmacother 2001; 35: 1056-1065. http://dx.doi.org/10.1345/aph.10223
7. GRUBBS CJ, LUBET RA, ATIGADDA VR, CHRISTOV K, DESHPANDE AM et al. Efficacy of new retinoids in the prevention of mammary cancers and correlations with shortterm biomarkers. Carcinogenesis 2006; 27: 1232-1239. http://dx.doi.org/10.1093/carcin/bgi308
8. QU L, TANG X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 2010; 65: 201-205. http://dx.doi.org/10.1007/s00280-009-1140-4
9. CHAMILOVA M, BOJKOVA B, KUBATKA P, KALICKA K, ADAMEKOVA E, et al. Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats by tamoxifen and melatonin: metabolic alterations. Biologia (Bratislava) 2001; 56: 565-571.
10. CHAMILOVA M, KUBATKA P, KALICKA K, ADAMEKOVA E, BOJKOVA B, et al. Chemoprevention of N-methyl-N-nitrosourea induced mammary carcinogenesis with raloxifene and melatonin: Metabolic changes in female rats. Acta Vet (Brno) 2002; 71: 235-242. http://dx.doi.org/10.2754/avb200271020235
11. LELBACH A, MUZES G, FEFER J. Current perspectives of catabolic mediators of cancer cachexia. Med Sci Monit 2007; 13: 168-173.
12. BLASK DE, SAUER LA, DAUCHY RT, HOLOWACHUK EW, RUHOFF MS et al. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 1999; 59: 4693-4701.
13. ANISIMOV VN. The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 2003; 46: 221-234. http://dx.doi.org/10.1016/S1040-8428(03)00021-0
14. COS S, SANCHEZ-BARCELO EJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21: 133-170. http://dx.doi.org/10.1006/frne.1999.0194
15. LISSONI P, PAOLOROSSI F, TANCINI G, BARNI S, ARDIZZOIA A et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32: 1340-1343. http://dx.doi.org/10.1016/0959-8049(96)00136-0
16. RUSSO J, RUSSO IH. Atlas and histologic classification of tumor of the rat mammary gland. J Mammary Gland Biol Neoplasia 2000; 5: 187-200. http://dx.doi.org/10.1023/A:1026443305758
17. BARTLETT GR. Phosphorus assay in column chromatography. Biol Chem 1959; 234: 466-468.
18. ZLATKIS A, ZAK B, BOYLE AJ. A new method for the direct determination of cholesterol. J Lab Clin Med 1953; 41: 486-490.
19. ROE JH, DAILEY R. The determination of glycogen with anthrone reagent. Analyt Biochem 1966; 15: 245-250. http://dx.doi.org/10.1016/0003-2697(66)90028-5
20. SATOH K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37-43. http://dx.doi.org/10.1016/0009-8981(78)90081-5
21. GUILLEMIN R, CLAYTON GW, SMITH JD, LIPSCOMB HS. Measurement of free corticosteroids in rat plasma: physiological validation of method. Endocrinology 1958; 63: 349-357. http://dx.doi.org/10.1210/endo-63-3-349
22. GOTTARDIS MM, BISCHOFF ED, SHIRLEY MA, WAGONER MA, LAMPH WW et al. Chemoprevention of mammary carcinoma by LGD 1069 (Targretin): an selective ligand. Cancer Res 1996; 56: 5566-5570.
23. BISCHOFF ED, GOTTARDIS MM, MOON TE, HEYMAN RA; Lamph WW. Beyond tamoxifen: the retinoid X receptor selective ligand LGD 1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479-484.
24. WU K, ZHANG Y, XU XC, HILL J, CELESTINO J et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002; 62: 6376-6380.
25. LUBET RA, CHRISTOV K, NUNEZ NP, HURSTING SD, STEELE VE et al. Efficacy of Targretin in methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis. Carcinogenesis 2005; 26: 441-448. http://dx.doi.org/10.1093/carcin/bgh338
26. SUH N, LAMPH WW, GLASEBROOK AL, GRESE TA, PALKOWITZ AD et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002; 8: 3270-3275.
27. TAN DX, HARDELAND R, MANCHESTER LC, PAREDES SD, KORKMAZ A et al. The changing biological roles of melatonin in evolution: from an antioxidant to signals of dakness, sexual selection and fitness. Biol Rev Camb Philos Soc 2010; 85: 607-623.
28. ORENDAS P, KASSAYOVA M, KAJO K, AHLERS I, KUBATKA P et al. Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. Neoplasma 2009; 56: 250-256. http://dx.doi.org/10.4149/neo_2009_03_252